Groninger Brings New RTU Filling Platform and Lifecycle Services Concept to INTERPHEX NYC

For INTERPHEX NYC, taking place April 21-23, groninger will debut a formalized service structure and put a high-throughput ready-to-use processing platform in front of industry decision-makers.¹ Its presentation will offer a focused look at where filling and closing technology is heading.

What Does a Structured Equipment Lifecycle Program Mean for Manufacturing Teams?

The show will mark the formal launch of groninger’s Lifecycle Solutions concept in North America, a service program that consolidates support across the full lifespan of filling and closing equipment, from initial commissioning through continuous optimization, modernization, and retrofit.¹ For manufacturing teams, a structured approach to equipment lifecycle management is increasingly tied to regulatory compliance and production continuity rather than being a discretionary add-on.

“Comprehensive services are no longer a nice-to-have; they are an essential part of value creation,”¹ says Christian Thieme, vice president of Sales & Marketing, groninger USA, in a press release. “Our customers expect support to begin long before an issue arises. They expect—rightly so—proximity, rapid response, and an infrastructure that operates in real time.”

The program’s launch coincides with a $14.2 million investment in a new North American headquarters facility currently under construction in Charlotte, North Carolina.¹ The expanded site will include significantly increased manufacturing, assembly, and service capabilities aimed at shortening response times for customers across the region.

“With this expansion, we’re laying the foundation the market needs now: shorter distances, direct points of contact, and on-site manufacturing that can respond within hours rather than days,”¹ says Philipp Hauser, CEO, groninger USA, in the press release.

As companies continue to shift priorities toward regional manufacturing, this kind of local infrastructure has direct implications for production scheduling, validation timelines, and the ability to respond quickly when equipment deviations occur.¹

How Is the Industry’s Shift Toward Prefilled Syringes Changing Equipment Requirements?

The show will also feature a working demonstration of the UFVN, groninger’s platform targeting the upper performance range of ready-to-use container processing.¹ Built for large production volumes, the system incorporates 100% in-process control: every container is checked inline, deviations are flagged in real time, and out-of-specification units are automatically rejected. The platform is designed to handle syringes, vials, and cartridges on a single technical configuration.

Dirk Schuster, global head of Sales, groninger’s Pharma division, noted, in the press release.¹ “We’re presenting this machine platform at the show because it demonstrates what’s possible when technology and experience converge: stable high performance across all ready-to-use formats. Today, pharmaceutical companies must be able to process syringes, vials, and cartridges on a single technical platform—safely, reproducibly, and without compromising throughput or process execution.”

Prefilled syringes are steadily displacing vials as the dominant primary packaging format, driven by patient usability requirements and growing regulatory expectations around combination product design.¹ Yet, many firms still initiate development programs around vials, often discovering mid-development that a changeover to syringes introduces significant technical and regulatory rework.

“Our customers want to see that high performance, container flexibility, and process reliability work not just on paper but in daily production,” Schuster added.

groninger’s Julian Petersen, global head of Business Development Pharma, stated, in the press release,¹ “We’re seeing that early decisions on formats and technologies are increasingly determining the speed and safety of later clinical and commercial phases. When component suppliers, contract development and manufacturing organizations, and equipment manufacturers collaborate from the start, risks can be reduced and development becomes significantly more robust.”

Petersen will be presenting at INTERPHEX NYC on a new approach to system prequalification: design-verified filling systems that have been validated on current-generation lines before a sponsor’s development program reaches them.¹ For pharmaceutical development teams, this translates to reduced interface complexity between container components and filling equipment, lower technical risk during scale-up, and a more predictable path from early clinical phases into commercial manufacturing.

What Other INTERPHEX Events Should Professionals Be Paying Attention To?

The conversations taking place at INTERPHEX NYC sit within a broader global dialogue.² At INTERPHEX Week Tokyo, running May 20–22 at Makuhari Messe, 35,000 pharmaceutical and biotech professionals are expected to gather for it. Its 320-session program spans manufacturing excellence, quality and compliance, supply resilience, and digital transformation. A featured session from Boehringer Ingelheim will address how aligning development and manufacturing reduces transfer risks and accelerates launch readiness, themes that resonate directly with the format and scale-up decisions discussed at INTERPHEX NYC.

References

1. groninger. At INTERPHEX NYC, groninger to introduce new “Lifecycle Solutions” concept and showcase efficient RTU processing equipment. News release. March 12, 2026.
2. INTERPHEX WEEK TOKYO 2026. Japan’s largest pharma gathering publishes full 320-session programme for May 2026. Press Release; Mar 11, 202